Compare Aurora Cannabis Inc (ACB) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Brookfield Infrastructure Partners (BIP) trades at $39.04, up 0.26% on the day, with a bullish technical signal and strong analyst support. The stock shows a high P/E ratio of 61.26 but attractive EV/EBITDA of 6.91, while recent earnings misses in Q4 2025 and Q1-Q2 2026 contrast with positive cash flow trends and a 2.6% net income margin. Recent news highlights dividend strength and corporate simplification efforts.

Outlook remains positive with a consensus price target of $44.67, offering ~14% upside, supported by bullish sentiment and infrastructure demand. Risks include earnings volatility, high debt-to-asset ratio of 69.68%, and macroeconomic pressures on profitability. The dividend yield and institutional interest provide stability, but execution on guidance is critical.